DXB 9.84% 55.0¢ dimerix limited

Not much of a poster here in recent years, but have been in DXB...

  1. 4,189 Posts.
    lightbulb Created with Sketch. 785
    Not much of a poster here in recent years, but have been in DXB since 2016.

    The inconclusive result in DKD the Phase 2 trial in 2020 was a disappointment (more a frustration since it might well have been the result of DMX-200 providing unexpected residual benefit post dosing). Dimerix took this in its stride - DKD on the backburner and full steam ahead with FSGS.

    Now we are at another inflection point: if the current trial results are positive and the FDA approves Phase 3, we could see a step change in Dimerix - not only running the FSGS trial, but also having the resources to revisit DKD and maybe even start pre-clinical work on DMX-700. DKD itself is a huge potential market.
    Last edited by dyeman: 10/03/24
 
watchlist Created with Sketch. Add DXB (ASX) to my watchlist
(20min delay)
Last
55.0¢
Change
-0.060(9.84%)
Mkt cap ! $302.3M
Open High Low Value Volume
60.5¢ 61.0¢ 55.0¢ $2.309M 4.010M

Buyers (Bids)

No. Vol. Price($)
9 137019 55.0¢
 

Sellers (Offers)

Price($) Vol. No.
55.5¢ 22500 1
View Market Depth
Last trade - 16.10pm 21/06/2024 (20 minute delay) ?
DXB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.